More News

19 May 2022

Almirall and Evotec enter into a multi-target alliance in Medical Dermatology

18 May 2022

BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen

17 May 2022

LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2

16 May 2022

AbbVie and Cugene Announce Collaboration in Autoimmune Diseases

16 May 2022

Remix Therapeutics Closes $70 Million Series B Financing

13 May 2022

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

12 May 2022

Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation

11 May 2022

Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases

10 May 2022

Pfizer to Acquire Biohaven Pharmaceuticals

9 May 2022

Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression

9 May 2022

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

4 May 2022

Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics

4 May 2022

Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics

2 May 2022

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

1 May 2022

Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions

1 May 2022

Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany

26 April 2022

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

26 April 2022

Update on Regulatory Submission for Aducanumab in the European Union

20 April 2022

VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders

20 April 2022

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

19 April 2022

Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers

14 April 2022

Ubix Therapeutics, SK Biopharmaceuticals enter into research collaboration agreement to develop novel therapeutics based on targeted protein degradation

13 April 2022

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

13 April 2022

Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease

13 April 2022

GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

13 April 2022

Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss

8 April 2022

Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule

8 April 2022

TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues

8 April 2022

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

7 April 2022

HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

TL1A Inhibitor Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Mesothelin-Targeted Immunotherapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Ustekinumab (Stelara) Biosimilars Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy